



GlaxoSmithKline Consumer  
Healthcare Pakistan Limited  
35-Dockyard Road,  
West Wharf,  
Karachi - 74000,  
Pakistan

UAN +92 21 111 475 725  
Fax +92 91 3220 1855  
[www.gsk.com.pk](http://www.gsk.com.pk)

2<sup>nd</sup> August 2019

### Material Information

On 1<sup>st</sup> August, GSK globally closed the transaction to form Joint Venture between GSK Consumer Healthcare and Pfizer Consumer Healthcare and are launching a new world-leading company focused on improving the everyday healthcare of consumers. This is the start of an incredible journey to create the **world's most innovative, best performing and trusted consumer healthcare** company.

This transformative move brings together fantastic brands including Sensodyne, Voltaren, Panadol, Advil, Centrum. Our combined portfolio strengthens our global category leadership positions focused on **helping people do more, feel better and live longer**. GSK will hold an equity interest of 68% and Pfizer will hold an equity interest of 32% of the new Joint Venture Company.

GSK Consumer Healthcare Pakistan Ltd is currently listed on the Pakistan Stock Exchange with 85.79% equity interest held by GSK Consumer Healthcare B.V. (Netherlands), which is a fully owned subsidiary of GSK Plc, UK. Following the creation of the JV, GSK Consumer Healthcare B.V. (Netherlands) shareholding will now be owned by the JV in the 68:32 proportion mentioned above.

As a result of Global JV creation there will be no change in near future in the current product portfolio of GSK Consumer Healthcare Pakistan Limited.

As we progress on the journey of creating the new GSK Consumer Healthcare, we will keep our shareholders updated on any local changes.

Regards,

Sohail Ahmed Matin  
Chief Executive Officer  
GSK Consumer Healthcare Pakistan Limited